Food and Drug Administration (FDA) Issues Avandia Safety Warning

Diabetes drug linked to heart attacks

The FDA advisory panel voted Wednesday to keep the controversial drug, Avandia on the market, but with warnings of “significant safety” concerns based on studies that link the drug to increased risk of heart attack. 17 members voted for stricter wanting labels and restrictions on the sale of the drug.

Avandia, a drug designed to treat Type-2 diabetes and hypoglycemia, is linked with the following severe side effects:

  • heart attacks
  • heart-related death
  • severe chest pain

Avandia was approved by the FDA in 1999 to help the 23 million Americans who suffer from Type 2 diabetes. The drug is designed to control the blood sugar levels of diabetics by increasing the body’s resistance to insulin. However, a study in the New England Journal of Medicine released in 2007 linked the medicine to a 43% increase in heart attack risks.

Dr. David Graham, associate director of drug safety for the FDA said Avandia could be linked to about 500 more heart attacks and 300 more cases of heart failure each month than competitor, Actos. He called for Avandia to be removed from the market in a February report.

Thousands of Colorado diabetics who take Avandia may be at risk for dangerous complications including heart attacks, heart-related deaths, or severe chest pain.

Heart attack symptoms and warning signs:

  • chest pain/discomfort
  • pain/discomfort in other areas of the upper body
  • shortness of breath
  • cold sweat, lightheadedness, or nausea

If you live in Colorado and have taken Avandia, please contact the personal injury attorneys at Bachus & Schanker, LLC, Colorado’s injury law firm, now at 303-736-6111. You can use the form on the left side of this page, or call us 24 hours a day at 303-736-6111 to talk about your case.

Tell Us What Happened to Your Family

Get your free case evaluation here.

Contact Us

main case intake form for use site wide
  • This field is for validation purposes and should be left unchanged.